Characteristics among CAT patients in California with 13 common cancers by CAT location, 2005-2017
| . | PE±DVT . | pDVT . | iDDVT . | LE-NOS DVT . |
|---|---|---|---|---|
| Variables . | n (%) . | n (%) . | n (%) . | n (%) . |
| All | 36 379 (58.7) | 13 717 (22.1) | 6841 (11.0) | 5066 (8.2) |
| Cancer site | ||||
| Breast | 4663 (61.0) | 1467 (19.2) | 776 (10.2) | 736 (9.6) |
| Prostate | 3877 (53.3) | 1769 (24.3) | 918 (12.6) | 707 (9.7) |
| Lung | 8838 (71.0) | 1714 (13.8) | 1156 (9.3) | 734 (5.9) |
| Colorectal | 4682 (56.3) | 2039 (24.5) | 880 (10.6) | 720 (8.7) |
| NHL | 2038 (51.6) | 1054 (26.7) | 509 (12.9) | 350 (8.9) |
| Bladder | 996 (43.4) | 793 (34.6) | 279 (12.2) | 227 (9.9) |
| Uterine | 1900 (53.4) | 968 (27.2) | 373 (10.5) | 319 (9.0) |
| Kidney | 1508 (54.2) | 792 (28.5) | 311 (11.2) | 170 (6.1) |
| Pancreatic | 2660 (57.8) | 1040 (22.6) | 553 (12.0) | 351 (7.6) |
| Stomach | 1315 (60.8) | 456 (21.1) | 237 (11.0) | 154 (7.1) |
| Ovarian | 1708 (59.4) | 633 (22.0) | 302 (10.5) | 233 (8.1) |
| Brain | 1269 (56.4) | 515 (22.9) | 280 (12.4) | 185 (8.2) |
| Myeloma | 925 (50.0) | 477 (25.8) | 267 (14.4) | 180 (9.7) |
| Year of cancer diagnosis | ||||
| 2005-2007 | 8999 (55.7) | 3606 (22.3) | 2001 (12.4) | 1555 (9.6) |
| 2008-2010 | 9434 (58.1) | 3671 (22.6) | 1876 (11.6) | 1251 (7.7) |
| 2011-2013 | 8677 (60.7) | 3155 (22.1) | 1580 (11.0) | 889 (6.2) |
| 2014-2017 | 9269 (60.5) | 3285 (21.5) | 1384 (9.0) | 1371 (9.0) |
| Stage at diagnosis | ||||
| Stage I | 5987 (58.5) | 2219 (21.7) | 1130 (11.0) | 896 (8.8) |
| Stage II | 6909 (56.2) | 2838 (23.1) | 1424 (11.6) | 1125 (9.1) |
| Stage III | 6646 (60.1) | 2373 (21.5) | 1119 (10.1) | 914 (8.3) |
| Stage IV | 12 671 (61.1) | 4401 (21.2) | 2232 (10.8) | 1432 (6.9) |
| Stage Unknown | 4166 (54.2) | 1886 (24.5) | 936 (12.2) | 699 (9.1) |
| . | PE±DVT . | pDVT . | iDDVT . | LE-NOS DVT . |
|---|---|---|---|---|
| Variables . | n (%) . | n (%) . | n (%) . | n (%) . |
| All | 36 379 (58.7) | 13 717 (22.1) | 6841 (11.0) | 5066 (8.2) |
| Cancer site | ||||
| Breast | 4663 (61.0) | 1467 (19.2) | 776 (10.2) | 736 (9.6) |
| Prostate | 3877 (53.3) | 1769 (24.3) | 918 (12.6) | 707 (9.7) |
| Lung | 8838 (71.0) | 1714 (13.8) | 1156 (9.3) | 734 (5.9) |
| Colorectal | 4682 (56.3) | 2039 (24.5) | 880 (10.6) | 720 (8.7) |
| NHL | 2038 (51.6) | 1054 (26.7) | 509 (12.9) | 350 (8.9) |
| Bladder | 996 (43.4) | 793 (34.6) | 279 (12.2) | 227 (9.9) |
| Uterine | 1900 (53.4) | 968 (27.2) | 373 (10.5) | 319 (9.0) |
| Kidney | 1508 (54.2) | 792 (28.5) | 311 (11.2) | 170 (6.1) |
| Pancreatic | 2660 (57.8) | 1040 (22.6) | 553 (12.0) | 351 (7.6) |
| Stomach | 1315 (60.8) | 456 (21.1) | 237 (11.0) | 154 (7.1) |
| Ovarian | 1708 (59.4) | 633 (22.0) | 302 (10.5) | 233 (8.1) |
| Brain | 1269 (56.4) | 515 (22.9) | 280 (12.4) | 185 (8.2) |
| Myeloma | 925 (50.0) | 477 (25.8) | 267 (14.4) | 180 (9.7) |
| Year of cancer diagnosis | ||||
| 2005-2007 | 8999 (55.7) | 3606 (22.3) | 2001 (12.4) | 1555 (9.6) |
| 2008-2010 | 9434 (58.1) | 3671 (22.6) | 1876 (11.6) | 1251 (7.7) |
| 2011-2013 | 8677 (60.7) | 3155 (22.1) | 1580 (11.0) | 889 (6.2) |
| 2014-2017 | 9269 (60.5) | 3285 (21.5) | 1384 (9.0) | 1371 (9.0) |
| Stage at diagnosis | ||||
| Stage I | 5987 (58.5) | 2219 (21.7) | 1130 (11.0) | 896 (8.8) |
| Stage II | 6909 (56.2) | 2838 (23.1) | 1424 (11.6) | 1125 (9.1) |
| Stage III | 6646 (60.1) | 2373 (21.5) | 1119 (10.1) | 914 (8.3) |
| Stage IV | 12 671 (61.1) | 4401 (21.2) | 2232 (10.8) | 1432 (6.9) |
| Stage Unknown | 4166 (54.2) | 1886 (24.5) | 936 (12.2) | 699 (9.1) |
Models are stratified by cancer site and adjusted for the competing risk of death using Fine and Gray methodologies.
Models are additionally adjusted for age at cancer diagnosis, stage at cancer diagnosis, initial course of treatment (chemotherapy, radiation, and surgery), neighborhood socioeconomic status, and health insurance at diagnosis or initial treatment. Variables that violated proportional hazard assumption were included as a stratification variable.
LE-NOS DVT, lower extremity, not otherwise specified deep vein thrombosis.